Slingshot Biosciences, Inc. Partners With Cambridge Bioscience to Distribute Synthetic Cells Throughout United Kingdom and Ireland

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science … [Read more…]

Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in-person of members of Sensorion’s senior management in the Inner Ear Disorder Therapeutics Summit, a … [Read more…]

Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries

OSAKA, Japan & GENEVA & BOSTON–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for … [Read more…]

Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries

OSAKA, Japan & GENEVA & BOSTON–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for … [Read more…]

Synopsis on the 1st IOF International Orthodontic Symposium

HONG KONG–(BUSINESS WIRE)–Orthodontics is the art of health and aesthetics that follows nature and portrays our pursuit of beauty. For thousands of years, orthodontists – the engineers and artists of orthodontics – have focused on providing healthier teeth and brighter smiles. From June 3rd to 5th, the 1st IOF International Orthodontic Symposium, hosted by International … [Read more…]

Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA

In the EPIC-SR study of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met, as previously reported Data from standard-risk patients, both vaccinated and unvaccinated, while not all statistically significant, are supportive of efficacy data observed in EPIC-HR study … [Read more…]

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentations from heart failure specialists, Dr. David D’Alessandro, Surgical Director, … [Read more…]

PURE Bioscience Reports Fiscal 2022 Third Quarter and Nine-Month Financial Results

Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2022. Q3: Summary of Results of Operations Net product sales for the fiscal … [Read more…]

DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans (AHIP) … [Read more…]

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in … [Read more…]